Skip to main content
. 2019 Nov 21;7:319. doi: 10.1186/s40425-019-0774-y

Fig. 4.

Fig. 4

Outcomes of immune checkpoint inhibitor-related myasthenia gravis according to first-line treatment. Group 1: Patients who received steroids without concurrent intravenous immunoglobulin or plasmapheresis in first-line treatment (n=38). Group 2: Patients who received intravenous immunoglobulin or plasmapheresis regardless of steroids in first-line treatment (n=19)